2. Search Result
Search Result
Results for "

cardioprotective effect

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N4195
    Resveratroloside
    1 Publications Verification

    Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside

    		 Glucosidase Cardiovascular Disease Metabolic Disease
    Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC50 of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .
    Resveratroloside
  • HY-103171
    BAY 60-6583
    4 Publications Verification

    		 Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    BAY 60-6583 is a potent and high-affinity agonist of adenosine A2B receptor (EC50?= 3 nM) over A1, A2A, and A3 receptors. BAY 60-6583 binds to mouse, rabbit, and dog A2BAR with Ki values of 750 nM, 340 nM and 330 nM, respectively. BAY 60-6583 has a cardioprotective effect in a myocardial ischemia model .
    BAY 60-6583
  • HY-125959
    Ucf-101
    1 Publications Verification

    		 Apoptosis Cardiovascular Disease Neurological Disease
    Ucf-101 is a selective and competitive inhibitor of pro-apoptotic protease Omi/HtrA2, with an IC50 of 9.5 μM for His-Omi. Ucf-101 exhibits very little activity against various other serine proteases (IC50>200 μM). Ucf-101 has a natural red fluorescence at 543 nm that is used to monitor its ability to enter mammalian cells. Ucf-101 has a significant cardioprotective effect against MI/R injury and also has certain neuroprotective effect .
    Ucf-101
  • HY-12184
    ONO-AE 248

    		Others Cardiovascular Disease
    ONO-AE 248 is a selective EP3 receptor agonist with cardioprotective activity. ONO-AE 248 reduces myocardial infarction size by selectively binding to the EP3α receptor in mice. The cardioprotective effect of ONO-AE 248 is independent of hemodynamic effects. The mechanism of ONO-AE 248 may involve activation of protein kinase C and opening of K(ATP) channels .
    ONO-AE 248
  • HY-17494A
    Timolol hemihydrate

    (S)-L-714,465 hemihydrate; MK 950 hemihydrate

    		 Adrenergic Receptor Infection Cancer
    Timolol (hemihydrate) is a β-blocker available for both topical and systemic administration. Timolol (hemihydrate) is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension and Timolol (hemihydrate) also has cardioprotective effect .
    Timolol hemihydrate
  • HY-108502
    KC 12291 hydrochloride

    		Sodium Channel Cardiovascular Disease
    KC 12291 hydrochloride is an orally active blocker of voltage-gated sodium channel (VGSC). KC 12291 hydrochloride reduces the amplitude of sustained Na + current to exert antiischemic activity. KC 12291 hydrochloride has significant cardioprotective effect in vitro and in vivo .
    KC 12291 hydrochloride
  • HY-161929
    GPX4 activator 2

    		Glutathione Peroxidase Ferroptosis Cardiovascular Disease
    GPX4 activator 2 (Compound C3) is an activator of GPX4. GPX4 activator 2 exhibits cardioprotective effects and can inhibit cellular ferroptosis (EC50 = 7.8 μM)。GPX4 activator 2 can be used in the research of myocardial injury .
    GPX4 activator 2
  • HY-N10593
    Ladanetin-6-O-β-D-glucopyranoside

    		Reactive Oxygen Species Cardiovascular Disease
    Ladanetin-6-O-β-D-glucopyranoside is an active flavonoid. Ladanetin-6-O-β-D-glucopyranoside has antioxidative effect. Ladanetin-6-O-β-D-glucopyranoside can be used for the research of cardioprotective effects .
    Ladanetin-6-O-β-D-glucopyranoside
  • HY-17494
    Timolol

    (S)-L-714,465; MK 950 free base

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol
  • HY-17494B
    Timolol hemimaleate

    (S)-L-714,465 hemimaleate; MK 950 hemimaleate

    		 Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol ((S)-L-714,465; MK 950) hemimaleate is a β-blocker available for both topical and systemic administration. Topical Timolol hemimaleate is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol hemimaleate can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol hemimaleate
  • HY-17494R
    Timolol (Standard)

    		Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Timolol (Standard) is the analytical standard of Timolol. This product is intended for research and analytical applications. Timolol is a β-blocker available for both topical and systemic administration. Topical Timolol is primarily used to reduce intraocular pressure with open-angle glaucoma and ocular hypertension. Timolol can also be used for the research of infantile hemangiomas, hypertension, myocardial infarction, migraine prophylaxis, and atrial fibrillation.Timolol also has cardioprotective effect .
    Timolol (Standard)
  • HY-P5762A
    Phoenixin-14 TFA

    PNX-14 TFA

    		 GnRH Receptor Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
    Phoenixin-14 (PNX-14) TFA, a BBB-penatrable neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH .
    Phoenixin-14 TFA
  • HY-121586
    Nafazatrom

    Bay g 6575

    		 Others Cardiovascular Disease
    Nafazatrom (Bay g 6575) is an orally active cardioprotective agent that protects against ischemic damage. Nafazatrom dose-dependently inhibits neutrophil aggregation, superoxide anion generation, arachidonic acid metabolism, and to a lesser extent the release of β-glucosidase, platelet aggregation or arachidonic acid in vitro. Acid metabolism has no significant effect. In a dog ischemia-reperfusion model, Nafazatrom (10 mg/kg; po) reduced infarct size and the occurrence of arrhythmias and rescued ischemic myocardial function without affecting any hemodynamic changes. The basis of Nafazatrom's cardioprotection may be inhibition of neutrophil function and cellular infiltration in vitro .
    Nafazatrom

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: